The future of meat keeps inventing itself, then running out of money to build the factory

Food & Farming 5 min 80 sources

A wave of lab-grown and insect-protein startups proved their food works — and then collapsed trying to scale it. Plus the EU loosens its rules on gene-edited crops, and a drought tightens America's corn belt.

Key takeaways

A wave of lab-grown meat and insect-protein startups proved their food works, then collapsed trying to build factories — the gap between a lab prototype and a profitable plant is where the money runs out.
The EU loosened its rules on gene-edited crops, letting lightly-edited CRISPR plants reach fields faster by no longer treating them as GMOs.
A drought has pushed parts of North Carolina into the most severe rating, and the USDA expects U.S. farm costs to hit record highs in 2027 — pressure that travels toward grocery prices.

This week the alternative-protein business kept doing the thing it has done for a decade: prove the science, win the headline, and then run out of road before it can build anything at scale.

The valley of death

Two stories landed within days of each other. In Australia, Goterra — an insect-farming firm that turns food waste into animal feed and was one of the industry’s earliest entrants — went into administration after running out of cash, and its administrator is now hunting for a buyer [7]. In Finland, Solar Foods, which makes protein by feeding hydrogen and carbon dioxide to microbes, secured €77.8 million ($89.2 million) in grants and loans toward its first commercial factory — but the money is contingent on raising more money, and the final decision to build hasn’t been made [24].

Put those together and you see the pattern that governs this whole sector. The technology works. Goterra had signed, long-term contracts for its product. Solar Foods makes a real protein and has regulatory clearance in Singapore and the US [24]. What kills these companies isn’t that the food fails — it’s that the factory fails to get built. Inventing a protein in a lab and manufacturing it cheaply at industrial scale are two completely different problems, and the second one is far harder and far more expensive. The industry has a name for the gap between them: the valley of death.

The numbers tell the story plainly. Investment in cultivated meat — real meat grown from animal cells, no slaughter — peaked at $989 million in 2021, then fell to $807 million in 2022, $177 million in 2023, and just $55 million in 2024 [3]. It crept back to $82.6 million in 2025, but only because of a single $17.6 million round for one company [3]. Two of the best-funded players, Believer Meats and Meatable, abruptly shut down in December [3]. The top-funded firm, UPSIDE Foods, has paused its large-scale Illinois plant [3].

Why a working product still can’t reach the shelf

The reason is economics, not biology. One investor put it bluntly: cultivated chicken “does not make sense” because conventional chicken has only gotten cheaper over 30 years — about a dollar a pound on a good day [3]. You cannot win on price against a product that is already that cheap and already that good at scaling. The few places the bet still looks sane are where the animal version is genuinely broken: bluefin tuna, which can’t be farmed and carries mercury and microplastics, has real pent-up demand [3].

So the survivors are narrowing their aim — high-value products where the ordinary supply chain is “really messed up,” in one investor’s words [3]. That is a quieter, smaller ambition than replacing the world’s burgers. It’s also probably the honest one.

A rare win — six years in the making

Not every story this week was a collapse. The Protein Brewery, a Dutch firm, won EU approval to sell Fermotein, a protein grown from fungus — the first novel mycelium ingredient cleared for sale in the bloc [9]. The catch: it took six years from filing to approval [9]. The company that helped pioneer the category, the maker of Quorn, had the EU market essentially to itself for years partly because the approval pipeline is so slow [9]. A food-policy group welcomed the decision but said six years “shows the need to ensure the regulatory framework keeps pace” [9]. Even when the science and the money line up, the clock can be the thing that breaks you.

The EU opens a door for gene-edited crops

On the farming side, the EU changed its rules on gene editing — and this one is genuinely consequential [2]. Until now, gene-edited crops were lumped in with genetically modified organisms (GMOs), which means an extensive risk assessment, strict labelling, and a slow road to market [2]. A 2018 court ruling had pulled even newer, more precise techniques into that net [2].

The new system splits gene-edited crops into two tiers. Crops with a limited number of changes — 20 or fewer — that could in principle have happened through ordinary breeding are now treated more lightly and no longer counted as GMOs [2]. More heavily engineered crops stay under the strict old rules [2]. The practical effect: CRISPR-edited crops — CRISPR is a precise tool for editing DNA, the work that won a 2020 Nobel Prize — can reach European fields faster [2]. The fight now moves to patents, and a worry that a few firms could lock up ownership of the seeds [2].

A drought tightens the corn belt

Closer to the dinner table, the weather is doing its slow work. Parts of North Carolina’s Piedmont have fallen into “exceptional drought,” the U.S. Drought Monitor’s most severe rating, with topsoil rated 20% very short and 52% short of moisture [4]. Corn there is “rolling” — curling its leaves to survive — while soybeans struggle [4].

The national picture is steadier: the USDA rated 68% of the U.S. corn crop good-to-excellent for the week ending June 21, with silking running ahead of the five-year average [14]. But the strain is building underneath. The USDA expects U.S. farm production costs to hit record highs in 2027 [5]. Higher costs to grow the crop don’t vanish — they travel down the chain toward the price you pay, eventually.

And the chocolate workaround

One last thread that connects to last week’s cocoa story. With cocoa prices still near historic highs, the German ingredients giant Döhler bought a British startup, Nukoko, that makes chocolate from fava beans instead of cocoa [67]. Cocoa-free chocolate is moving “from niche to mainstream, fast,” the trade press reports, as makers look past tweaks toward entirely new raw materials [67]. Meanwhile Lindt said it now sources 100% of its cocoa from farms certified on labour and environmental standards [78]. Two different answers to the same squeeze: replace the bean, or fix the farm it comes from.

02 · Lesson · why it matters

The hardest part isn't inventing the thing — it's building the second one a million times

A working prototype and a profitable factory are two different achievements, and most good ideas die in the gap between them.

A demo is not a business

This week several companies that make protein in new ways — from microbes, from fungus, from insects fed on food waste — proved something real. Their food works. It tastes right, it’s safe, regulators have signed off in some markets. And several of them collapsed anyway.

That gap is worth sitting with, because it shows up everywhere. We instinctively think the hard part of any new thing is the invention — the spark, the breakthrough, the first one that works. So when something is invented, we assume it’s basically done. The work that’s left feels like a formality: just make more of it.

It isn’t a formality. It’s a second invention, and usually a harder one.

The first one is a craft; the millionth is a machine

Making one of something is a craft problem. You can hand-tune it, fuss over it, spend whatever it takes. Making a million of something cheaply is a completely different problem — it’s about machines, energy, supply, waste, and most of all cost per unit. None of the skill that produced the first one tells you how to produce the millionth at a price anyone will pay.

A cell-grown chicken breast can be made. The question that kills the company is whether it can be made for less than a dollar a pound — because ordinary chicken already costs about that, and has been getting cheaper for thirty years. The lab solved “can we.” The factory has to solve “can we, cheaply, forever, against a rival that’s been doing it at scale for a century.” Those are not the same question, and winning the first tells you almost nothing about the second.

The valley of death

Investors have a name for the place these companies fall into: the valley of death. It’s the stretch between a working pilot and a profitable plant — too proven to be a science experiment, too unproven to be a safe bet. The pilot worked, so the easy excitement is spent. The factory hasn’t paid off yet, so the patient money hasn’t arrived. In between, you burn cash building something enormous on a promise.

Goterra had signed contracts for its insect protein and still ran out of road. Solar Foods won most of the money for its factory — but the money is contingent on raising more money, and the build hasn’t started. The cleared product, the real demand, the partial funding: none of it carries you across. The crossing is its own thing, and it’s where the bodies pile up. Money for this whole sector fell from nearly a billion dollars a year to a small fraction of that, not because the food got worse, but because investors learned how long and how expensive the crossing is.

The clock is part of the gap

Time is the quiet third party in all of this. The Protein Brewery got its fungus-protein approved in Europe this week — six years after it filed. The science was ready long before the paperwork was. Six years is enough to drain a company that did everything right, and enough for a rival to keep a market to itself simply by being early through a slow door.

Scaling isn’t only about money and machines. It’s about how many seasons you can survive while the world catches up — the regulators, the supply chains, the customers, the cost curve. A thing can be invented, funded, and still die of waiting.

Who else is standing in this valley

This isn’t a story about lab meat. It’s the shape of almost everything that has to leave the lab and enter the world. The battery that works in a cell but not in a car. The drug that cures mice but can’t be manufactured at scale. The clean fuel that’s real in a beaker and ruinous by the tanker. The same gap sits under each: a working first, a long valley, a profitable second that may never come.

It’s worth remembering the next time a headline announces that something has been “invented” — a cure, a fuel, a food that will change everything. The invention is real. It’s also the easy half. The thing standing between that headline and your actual life is the factory, the cost, and the years — and most of what gets invented never makes it across. Knowing that doesn’t make you a cynic. It makes you slower to believe that a breakthrough and a finished thing are the same, and a little humbler about how much of the world’s progress is quietly stuck in the valley, working perfectly, going nowhere yet.

03 · Lab · your turn

Crossing the Valley of Death

Spend a startup's finite runway over four years to turn a working prototype into a profitable factory — and feel how a good product still dies in the gap.

04 · Hope · carry this

For every company that ran out of road this week, someone is starting the crossing again — a little wiser about how long it takes, and still convinced it's worth building. That stubborn patience, repeated across decades, is how almost everything we now take for granted finally reached the shelf.